Skip To Main Content

Differential Diagnostics for ASMD in Patients Suspected to have GD

 

Objective

To demonstrate

 

of differential diagnosis

Primary diagnostic testing

Improve detection rate of potential
ASMD 
Avoid diagnostic delays

 

A multicenter, prospective study

DBS testing

GBA enzyme activity


ASM enzyme activity

 

Genetic confirmatory testing

 

Results

Genetic confirmatory testing done for 5933 cases

SMPD1 gene sequencing for 1171 cases GBA gene sequencing for 4762 cases

ASMD:GD varies by region

 

Overall, 1 out of 4 patients with suspected GD suffered from ASMD.

 

Overall, 51% of ASMD cases were newborns.

 <28 days

 10-18 years

 28 days to <10 years

>18 years

 

5933 symptomatic cases showed decreased enzyme activities

 

227 distinct SMPD1 sequence variants identified

 

10 more frequent variants

 

  

Most of the cases with ASMD from the Middle East were newborns and with GD were adults.

Color by:
Gene-ID

 

Age group

GBA  Adults (>18 years)
GBA  Children (below 10 years)
GBA  Children/adolescents (10–18 years)
GBA  Newborns
 SMPD1  Adults (>18 years)
 SMPD1  Children (below 10 years)
SMPD1  Children/adolescents (10–18 years)
SMPD1  Newborns

 

 

Higher number of confirmed ASMD patients in Pakistan, Iraq, Turkey, and Iran

Egypt had the highest number of GD cases followed by Turkey, while Iraq had the highest number of ASMD cases.


Conclusion

Abbreviations

ASM: Acid sphingomyelinase; ASMD: Acid sphingomyelinase deficiency; DBS: Dried blood spots; GBA: Acid- -glucocerebrosidase; GD: Gaucher disease; KSA: Kingdom of Saudi Arabia; SMPD1: Sphingomyelin phosphodiesterase 1; UAE: United Arab Emirates.

MAT-BH-2400114-V1-February 2024